Press release

Teikoku Seiyaku Co., Ltd.
Mitsubishi Tanabe Pharma Corporation

Notice regarding acquisition of manufacturing and sales approval for Rupafin® tablets
Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)

Teikoku Seiyaku Co., Ltd. (Head Office: Higashikagawa City, Kagawa; President and CEO: Misako Fujioka) and Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka City; President and Representative Director: Masayuki Mitsuka) have announced that on September 27, 2017, Teikoku Seiyaku acquired manufacturing and sales approval for anti-allergy agent Rupafin® tablets (generic name: rupatadine fumarate). Rupafin® has indications of allergic rhinitis, urticaria, and pruritus accompanying skin disease (eczema, dermatitis, prurigo, cutaneous pruritus).

This oral allergy treatment agent has a new mechanism of action. In addition to antihistamine action, Rupafin® tablets also have anti-PAF (platelet activating factor) action. Histamine is widely known as a chemical mediator that brings about allergic reactions. PAF induces vasodilation, vascular permeability enhancement, vascular nerve stimulation, and white blood cell activation. As a result, it brings about such symptoms as sneezing, runny nose, and nasal congestion, and it is closely involved in the pathology of allergic disorders. Rupafin® tablets control these two chemical mediators and show strong dual action (anti-PAF and antihistamine), thereby controlling the symptoms of allergic disorders.

This drug was discovered by J. Uriach Y COMPANIA, S.A., of Spain, and had been approved in more than 80 countries around the world as of September 2017. Overseas, it has indications of allergic rhinitis and urticaria and is administered orally at a dosage of 10mg once a day. In Japan, in May 2014 Teikoku Seiyaku concluded a development and sales licensing agreement with J. Uriach Y COMPANIA, and Teikoku Seiyaku has advanced development on its own.

In October 2016, Teikoku Seiyaku and Mitsubishi Tanabe Pharma reached a basic agreement for sales of Rupafin® tablets. Teikoku Seiyaku will supply the product to Mitsubishi Tanabe Pharma, which will distribute and market it. In addition, the two companies will jointly implement information provision activities for medical institutions.

For further information, please contact:

<table>
<thead>
<tr>
<th>Teikoku Seiyaku Co., Ltd., General Affairs Department</th>
<th>Mitsubishi Tanabe Pharma Corporation Corporate Communications Department</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tel: +81-3-3661-3331</td>
<td>Tel:+81-6-6205-5211</td>
</tr>
</tbody>
</table>